HK1201202A1 - Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia - Google Patents
Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemiaInfo
- Publication number
- HK1201202A1 HK1201202A1 HK15101815.4A HK15101815A HK1201202A1 HK 1201202 A1 HK1201202 A1 HK 1201202A1 HK 15101815 A HK15101815 A HK 15101815A HK 1201202 A1 HK1201202 A1 HK 1201202A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- myeloid leukaemia
- treating acute
- novel combinations
- acute myeloid
- chronic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12305295.3A EP2638911A1 (en) | 2012-03-14 | 2012-03-14 | Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia |
PCT/EP2013/055137 WO2013135766A1 (en) | 2012-03-14 | 2013-03-13 | Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1201202A1 true HK1201202A1 (en) | 2015-08-28 |
Family
ID=48040161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15101815.4A HK1201202A1 (en) | 2012-03-14 | 2015-02-18 | Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia |
Country Status (19)
Country | Link |
---|---|
US (1) | US20150005253A1 (xx) |
EP (2) | EP2638911A1 (xx) |
JP (1) | JP2015509967A (xx) |
KR (1) | KR20140138885A (xx) |
CN (1) | CN104302298A (xx) |
AU (1) | AU2013231227A1 (xx) |
CA (1) | CA2866993A1 (xx) |
CL (1) | CL2014002434A1 (xx) |
CO (1) | CO7071130A2 (xx) |
CR (1) | CR20140414A (xx) |
DO (1) | DOP2014000206A (xx) |
EA (1) | EA201491682A1 (xx) |
HK (1) | HK1201202A1 (xx) |
MA (1) | MA35938B1 (xx) |
MX (1) | MX2014011054A (xx) |
PH (1) | PH12014502020A1 (xx) |
SG (1) | SG11201405566QA (xx) |
TN (1) | TN2014000382A1 (xx) |
WO (1) | WO2013135766A1 (xx) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109963571A (zh) * | 2016-09-16 | 2019-07-02 | 拜奥-帕斯控股股份有限公司 | 含有脂质体反义寡核苷酸的组合疗法 |
CN108280321B (zh) * | 2018-01-29 | 2021-09-17 | 沈阳药科大学 | 基于细胞代谢轮廓分析构建抗肿瘤候选化合物作用机制预测模型的方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2887882B1 (fr) * | 2005-07-01 | 2007-09-07 | Sanofi Aventis Sa | Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique |
FR2910813B1 (fr) | 2006-12-28 | 2009-02-06 | Sanofi Aventis Sa | Nouvelle utilisation therapeutique pour le traitement des leucemies |
-
2012
- 2012-03-14 EP EP12305295.3A patent/EP2638911A1/en not_active Withdrawn
-
2013
- 2013-03-13 AU AU2013231227A patent/AU2013231227A1/en not_active Abandoned
- 2013-03-13 CN CN201380025090.3A patent/CN104302298A/zh active Pending
- 2013-03-13 SG SG11201405566QA patent/SG11201405566QA/en unknown
- 2013-03-13 CA CA2866993A patent/CA2866993A1/en not_active Abandoned
- 2013-03-13 KR KR1020147028287A patent/KR20140138885A/ko not_active Application Discontinuation
- 2013-03-13 EP EP13713102.5A patent/EP2825177A1/en not_active Withdrawn
- 2013-03-13 WO PCT/EP2013/055137 patent/WO2013135766A1/en active Application Filing
- 2013-03-13 MX MX2014011054A patent/MX2014011054A/es unknown
- 2013-03-13 JP JP2014561435A patent/JP2015509967A/ja active Pending
- 2013-03-13 EA EA201491682A patent/EA201491682A1/ru unknown
-
2014
- 2014-09-09 CR CR20140414A patent/CR20140414A/es unknown
- 2014-09-10 TN TNP2014000382A patent/TN2014000382A1/fr unknown
- 2014-09-10 PH PH12014502020A patent/PH12014502020A1/en unknown
- 2014-09-11 CO CO14200660A patent/CO7071130A2/es unknown
- 2014-09-11 DO DO2014000206A patent/DOP2014000206A/es unknown
- 2014-09-12 CL CL2014002434A patent/CL2014002434A1/es unknown
- 2014-09-12 US US14/484,948 patent/US20150005253A1/en not_active Abandoned
- 2014-09-17 MA MA37352A patent/MA35938B1/fr unknown
-
2015
- 2015-02-18 HK HK15101815.4A patent/HK1201202A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
DOP2014000206A (es) | 2014-10-31 |
CA2866993A1 (en) | 2013-09-19 |
AU2013231227A1 (en) | 2014-10-02 |
JP2015509967A (ja) | 2015-04-02 |
CL2014002434A1 (es) | 2014-12-19 |
EP2638911A1 (en) | 2013-09-18 |
US20150005253A1 (en) | 2015-01-01 |
MA35938B1 (fr) | 2014-12-01 |
EA201491682A1 (ru) | 2015-01-30 |
TN2014000382A1 (en) | 2015-12-21 |
MX2014011054A (es) | 2015-02-05 |
CN104302298A (zh) | 2015-01-21 |
CO7071130A2 (es) | 2014-09-30 |
EP2825177A1 (en) | 2015-01-21 |
CR20140414A (es) | 2015-02-06 |
KR20140138885A (ko) | 2014-12-04 |
WO2013135766A1 (en) | 2013-09-19 |
SG11201405566QA (en) | 2014-10-30 |
PH12014502020A1 (en) | 2014-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1214504A1 (zh) | 用於治療貧血的方法 | |
HK1222808A1 (zh) | 急性骨髓性白血病 的新型組合治療 | |
GB2514037B (en) | Systems for treating complex fistulae | |
EP2875826A4 (en) | COMPOSITION FOR PREVENTING OR TREATING SEPSIS | |
GB201219873D0 (en) | Diverticulitis treatment | |
EP2921510A4 (en) | SURFACE TREATMENT COMPOSITION | |
HK1199204A1 (en) | Composition for preventing or treating hangover | |
LT2906219T (lt) | Orvepitantas, skirtas lėtinio niežulio gydymui | |
SG10201700525PA (en) | Composition for preventing or treating osteoarthritis | |
ZA201503005B (en) | Ingenol-derived compounds useful for treating cancer | |
EP2812190A4 (en) | SURFACE TREATMENT COMPOSITION | |
IL238606B (en) | CD44v6-derivative peptides for the treatment of cancer metastases | |
EP2917374A4 (en) | TECHNIQUES FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA (LAL) | |
EP2844929A4 (en) | RAIL CLAMP | |
HK1201202A1 (en) | Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia | |
ZA201406172B (en) | Compounds and methods for treating leukemia | |
EP2908813A4 (en) | COMPOUNDS FOR TREATING RAC-GTPASE MEDIA DISORDER | |
HK1209040A1 (en) | Methods for treating vestibulotoxicity | |
EP2854774A4 (en) | METHODS OF TREATING INSOMNIA | |
GB201321531D0 (en) | Treatment for cancers | |
GB201313159D0 (en) | Finishing Treatment | |
GB201216539D0 (en) | Epithelial treatment | |
GB201211135D0 (en) | Treatment | |
GB201208690D0 (en) | Treatment | |
AU2012060V (en) | Supechseventeen Prunus persica |